This article has been updated from a version posted Sept. 19 to include comments from Illumina officials.
Illumina's acquisition of BlueGnome, announced last week, will broaden the San Diego firm's opportunities in molecular diagnostics, according to its top executive.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.